Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (trading symbol: VIRI) on May 2, 2023. The filing addresses a material event regarding the company's continued listing status on the Nasdaq Capital Market. Note: The request metadata referenced "Dogwood Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Virios Therapeutics, Inc.
Key Financial Metrics
This filing is a notification of a corporate governance event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the extension of a compliance period regarding Nasdaq listing rules:
- Deficiency: The company failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days, as notified by Nasdaq on November 1, 2022.
- Initial Period: The initial 180-day compliance period expired on May 1, 2023.
- Extension Granted: On May 2, 2023, Nasdaq granted an additional 180-day compliance period, extending the deadline to October 30, 2023.
- Conditions: The extension was granted because the company met all other listing requirements (including market value of publicly held shares) and submitted a written notice of intent to cure the deficiency, potentially via a reverse stock split.
Outlook, Risks, and Contingencies
Management and Nasdaq have outlined the following risks and contingencies:
- Delisting Risk: If the company fails to demonstrate compliance with the $1.00 minimum bid price by October 30, 2023, Nasdaq will notify the company that its common stock could be delisted.
- Appeal Process: In the event of a delisting determination, the company retains the right to appeal to a Nasdaq Hearings Panel.
- Uncertainty: The filing explicitly states there can be no assurance that the company will be able to regain compliance or maintain its listing on the Nasdaq Stock Market.
Investor Verification Checklist
- Verify the current trading price of VIRI to assess the likelihood of meeting the $1.00 bid price requirement by October 30, 2023.
- Monitor for future announcements regarding the execution of a reverse stock split as a potential cure mechanism.
- Review the company's most recent 10-K or 10-Q filings for financial health indicators, as this 8-K contains no financial data.
- Confirm the company's status on the Nasdaq Capital Market listing status page for any updates prior to the October 30, 2023 deadline.